Cancer UrologyCancer UrologyОнкоурология1726-97761996-1812Publishing House ABV Press134610.17650/1726-9776-2020-16-4-172-180REVIEWОБЗОРThe role of microRNA in the diagnosis of prostate cancerРоль микроРНК в диагностике рака предстательной железыhttps://orcid.org/0000-0003-2863-9001DolotkazinD. R.ДолотказинД. Р.
Russian Federation

3 2nd Botkinskiy Proezd, Moscow 125284

Данияр Рустамович Долотказин

125284 Москва, 2-й Боткинский проезд, 3

daniyar.dolotkazin@gmail.comhttps://orcid.org/0000-0002-6668-5028ShkurnikovM. Yu.ШкурниковМ. Ю.
Russian Federation

3 2nd Botkinskiy Proezd, Moscow 125284

125284 Москва, 2-й Боткинский проезд, 3

https://orcid.org/0000-0002-3398-4128AlekseevB. Ya.АлексеевБ. Я.
Russian Federation

Department of Oncology MSUFP

3 2nd Botkinskiy Proezd, Moscow 125284; 11 Volokolamskoe Shosse, Moscow 125080

Кафедра онкологии МГУПП.

125284 Москва, 2-й Боткинский проезд, 3; 125080 Москва, Волоколамское шоссе, 11

P.A. Hertzen Moscow Oncology Research Institute — branch of the National Medical Research Radiological Center, Ministry of Health of RussiaМосковский научно-исследовательский онкологический институт им. П.А. Герцена — филиал ФГБУ Национальный медицинский исследовательский центр радиологии Минздрава РоссииMedical Institute of Continuing Education, Moscow State University of Food ProductionМедицинский институт непрерывного образования, ФГБОУ ВО Московский государственный университет пищевых производств301220201641721802709202021102020https://oncourology.abvpress.ru/oncur/article/view/1346

Prostate cancer is the actual problem of oncourology due to the steady increase in incidence. Despite active use of prostate cancer screening methods and introduction of new diagnostic markers into practice, the problem of overdiagnosis and over-treatment of this disease remains selevant.

MicroRNAs are a promising biomarker, whose diagnostic and prognostic significance for prostate cancer is being actively studied now. This review provides information on microRNAs detected in the tissues of the prostate gland, blood and urine of patients with prostate cancer.

Рак предстательной железы представляет актуальную проблему онкоурологии по причине неуклонного роста показателей заболеваемости. Несмотря на широкое распространение методов скрининга рака предстательной железы и внедрение в практику новых диагностических маркеров, сохраняется актуальность проблемы гипердиагностики и чрезмерного лечения данного заболевания. МикроРНК являются перспективным биомаркером, чья диагностическая и прогностическая значимость для рака предстательной железы в настоящее время активно изучается. В представленном обзоре приведены сведения о микроРНК, определяемых в тканях предстательной железы, крови и моче больных раком предстательной железы.

prostate cancerdiagnosisbiomarkerexpressionmicroRNAрак предстательной железыдиагностикабиомаркерэкспрессиямикроРНКMalignant tumors in Russia in 2015 (morbidity and mortality). Eds.: A.D. Kaprin, V.V. Starinskiy, G.V. Petrova. Moscow: MNIOI im. P.A. Gertsena - filial FGBU “NMITS radiologii” Minzdrava Rossii, 2017. 250 p. (In Russ.).Злокачественные новообразования в России в 2015 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М.: МНИОИ им. П.А. Герцена - филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2017. 250 с.Woolf S.H. The accuracy and effectiveness of routine population screening with mammography, prostate-specific antigen, and prenatal ultrasound: a review of published scientific evidence. Int J Technol Assess Health Care 2001;17(3):275-304. DOI: 10.1017/s0266462301106021.Schroder F.H., van der Maas P., Beemsterboer P. et al. Evaluation of the digital rectal examination as a screening test for prostate cancer. Rotterdam section of the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 1998;90(23):1817-23. DOI: 10.1093/jnci/90.23.1817.Crawford E.D., Leewansangtong S., Goktas S. et al. Efficiency of prostatespecific antigen and digital rectal examination in screening, using 4.0 ng/ml and age-specific reference range as a cutoff for abnormal values. Prostate 1999;38(4):296-302. DOI: 10.1002/(sici)1097-0045(19990301)38:4<296::aid-pros5>3.0.co;2-p.Luo Y., Gou X., Huang P., Mou C. Prostate cancer antigen 3 test for prostate biopsy decision: a systematic review and meta analysis. Chin Med J 2014;127(9):1768-74.Cornu J.N., Cancel-Tassin G., Egrot C. et al. Urine TMPRSS2:ERG fusion transcript integrated with PCA3 score, genotyping, and biological features are correlated to the results of prostatic biopsies in men at risk of prostate cancer. Prostate 2013;73(3):242-9. DOI: 10.1002/pros.22563.Dijkstra S., Birker I.L., Smit F.P. et al. Prostate cancer biomarker profiles in urinary sediments and exosomes. J Urol 2014;191(4):1132-8. DOI: 10.1016/j.juro.2013.11.001.He L., Hannon G.J. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet 2004;5(7):522-31. DOI: 10.1038/nrg1379. Erratum in: Nat Rev Genet 2004;5(8):631.Calin G.A., Dumitru C.D., Shimizu M. et al. Frequent deletions and downregulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2002;99(24):15524-9. DOI: 10.1073/pnas.242606799.Cho W.C. MicroRNAs: potential biomarkers for cancer diagnosis, prognosis and targets for therapy. Int J Biochem Cell Biol 2010;42(8):1273-81. DOI: 10.1016/j.biocel.2009.12.014.Perge P., Nagy Z., Igaz I., Igaz P. Suggested roles for microRNA in tumors. Biomol Concepts 2015;6(2):149-55. DOI: 10.1515/bmc-2015-0002.Lawrie C.H., Gal S., Dunlop H.M. et al. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol 2008;141(5):672-5. DOI: 10.1111/j.1365-2141.2008.07077.x.Volinia S., Calin G.A., Liu C.G. et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 2006;103(7):2257-61. DOI: 10.1073/pnas.0510565103.Porkka K.P., Pfeiffer M.J., Waltering K.K. et al. MicroRNA expression profiling in prostate cancer. Cancer Res 2007;67(13):6130-5. DOI: 10.1158/0008-5472.CAN-07-0533.Carlsson J., Davidsson S., Helenius G. et al. A miRNA expression signature that separates between normal and malignant prostate tissues. Cancer Cell Int 2011;11(1):14. DOI: 10.1186/1475-2867-11-14.Srivastava A., Goldberger H., Dimtchev A. et al. MicroRNA profiling in prostate cancer - the diagnostic potential of urinary miR-205 and miR-214. PLoS One 2013;8(10):e76994. DOI: 10.1371/journal.pone.0076994.Hellwinkel O.J., Sellier C., Sylvester Y.M. et al. A Cancer-indicative microRNA pattern in normal prostate tissue. Int J Mol Sci 2013;14(3):5239-49. DOI: 10.3390/ijms14035239.S0kilde R., Vincent M., M0ller A.K. et al. Efficient identification of miRNAs for classification of tumor origin. J Mol Diagn 2014;16(1):106-15. DOI: 10.1016/j.jmoldx.2013.10.001.Mitchell P.S., Parkin R.K., Kroh E.M. et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 2008;105(30):10513-8. DOI: 10.1073/pnas.0804549105.Chen Z.H., Zhang G.L., Li H.R. et al. A panel of five circulating microRNAs as potential biomarkers for prostate cancer. Prostate 2012;72(13):1443-52. DOI: 10.1002/pros.22495.Srivastava A., Goldberger H., Dimtchev A. et al. Circulatory miR-628-5p is downregulated in prostate cancer patients. Tumour Biol 2014;35(5):4867-73. DOI: 10.1007/s13277-014-1638-1.Nguyen H.C., Xie W., Yang M. et al. Expression differences of circulating microRNAs in metastatic castration resistant prostate cancer and low-risk, localized prostate cancer. Prostate 2013;73(4):346-54. DOI: 10.1002/pros.22572.Moltzahn F., Olshen A.B., Baehner L. et al. Microfluidic-based multiplex qRT-PCR identifies diagnostic and prognostic microRNA signatures in the sera of prostate cancer patients. Cancer Res 2011;71(2):550-60. DOI: 10.1158/0008-5472.CAN-10-1229.Watahiki A., Macfarlane R.J., Gleave M.E. et al. Plasma miRNAs as biomarkers to identify patients with castrationresistant metastatic prostate cancer. Int J Mol Sci 2013;14(4):7757-70. DOI: 10.3390/ijms14047757.Shen J., Hruby G.W., McKiernan J.M. et al. Dysregulation of circulating microRNAs and prediction of aggressive prostate cancer. Prostate 2012;72(13):1469-77. DOI: 10.1002/pros.22499.Wang S.Y., Shiboski S., Belair C.D. et al. miR-19, miR-345, miR-519c-5p serum levels predict adverse pathology in prostate cancer patients eligible for active surveillance. PLoS One 2014;9(6):e98597. DOI: 10.1371/journal.pone.0098597.Weber J.A., Baxter D.H., Zhang S. et al. The microRNA spectrum in 12 body fluids. Clin Chem 2010;56(11):1733-41. DOI: 10.1373/clinchem.2010.147405.Hessels D., Klein Gunnewiek J.M., van Oort I. et al. DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol 2003 Jul;44(1):8-15; discussion 15-6. DOI: 10.1016/s0302-2838(03)00201-x.Mlcochova H., Hezova R., Stanik M., Slaby O. Urine microRNAs as potential noninvasive biomarkers in urologic cancers. Urol Oncol 2014;32(1):41.e1-9. DOI: 10.1016/j.urolonc.2013.04.011.Salido-Guadarrama A.I., Morales-Montor J.G., Rangel-Escareno C. et al. Urinary microRNA-based signature improves accuracy of detection of clinically relevant prostate cancer within the prostate-specific antigen grey zone. Mol Med Rep 2016;13(6):4549-60. DOI: 10.3892/mmr.2016.5095.Korzeniewski N., Tosev G., Pahernik S. et al. Identification of cell-free microRNAs in the urine of patients with prostate cancer. Urol Oncol 2015;33(1):16.e17-22. DOI: 10.1016/j.urolonc.2014.09.015.Casanova-Salas I., Rubio-Briones J., Calatrava A. et al. Identification of miR-187 and miR-182 as biomarkers of early diagnosis and prognosis in patients with prostate cancer treated with radical prostatectomy. J Urol 2014;192(1):252-9. DOI: 10.1016/j.juro.2014.01.107.Yun S.J., Jeong P., Kang H.W. et al. Urinary MicroRNAs of prostate cancer: virus-encoded hsv1-miRH18 and hsv2-miR-H9-5p could be valuable diagnostic markers. Int Neurourol J 2015;19(2):74-84. DOI: 10.5213/inj.2015.19.2.74.Stuopelyte K., Daniunaite K., Bakavicius A. et al. The utility of urine-circulating miRNAs for detection of prostate cancer. Br J Cancer 2016;115(6):707-15. DOI: 10.1038/bjc.2016.233.Bryant R.J., Pawlowski T., Catto J.W. et al. Changes in circulating microRNA levels associated with prostate cancer. Br J Cancer 2012;106(4):768-74. DOI: 10.1038/bjc.2011.595.Sapre N., Hong M.K., Macintyre G. et al. Curated microRNAs in urine and blood fail to validate as predictive biomarkers for high-risk prostate cancer. PLoS One 2014;9(4):e91729. DOI: 10.1371/journal.pone.0091729.Haj-Ahmad T.A., Abdalla M.A., Haj-Ahmad Y. Potential urinary miRNA biomarker candidates for the accurate detection of prostate cancer among benign prostatic hyperplasia patients. J Cancer 2014;5(3):182-91. DOI: 10.7150/jca.6799.Lewis H., Lance R., Troyer D. et al. miR-888 is an expressed prostatic secretions-derived microRNA that promotes prostate cell growth and migration. Cell Cycle 2014;13(2):227-39. DOI: 10.4161/cc.26984.Freds0e J., Rasmussen A.K.I., Thomsen A.R. Diagnostic and prognostic microRNA biomarkers for prostate cancer in cell-free urine. Eur Urol Focus 2018;4(6):825-33. DOI: 10.1016/j.euf.2017.02.018.Ahumada-Tamayo S., Saavedra-Briones D., Cantellano-Orozco M. et al. MicroRNA determination in urine for prostate cancer detection in Mexican patients at the Hospital General “Dr.Manuel Gea Gonzalez”. Rev Mex Urol 2011;71:213-7.